Innovate. Differentiate. Grow.
Proone Labs offers a comprehensive array of services, from early-stage business development to preclinical pharmacology and IND support, catering to the evolving needs of the biotech sector.
Preclinical Strategy & Execution
At Proone Labs, we provide expert, personalized strategic support to both innovators forging new paths in big pharma with their cutting-edge technology and ideas, as well as to established industry leaders.
Explore more
Success Stories
by our participation
30+
Assays developed for targets
50+
Cell lines developed
3
FDA drug approvals
5
Disease areas
IND submissions
15+
Analytical methods developed
4
Successfully funded startups
10+
Partnerships
Proone Labs provides expert services to
Traditional Pharma
Empowering Small and Mid-Sized Pharma to Innovate and Excel
Proone Labs assists small and mid-sized pharmaceutical companies in navigating the challenges of developing and commercializing innovative drugs. These challenges encompass limited resources, intricate R&D processes, regulatory hurdles, securing funding, and more.
Proone Labs assists small and mid-sized pharmaceutical companies in navigating the challenges of developing and commercializing innovative drugs. These challenges encompass limited resources, intricate R&D processes, regulatory hurdles, securing funding, and more.
Antibodies, ADC’s
Cell Reprogramming/iPSC Generation
Small Molecule PK/PD/TK
CRISPR Editing
Proteomics & Metabolomics
Ph
Pharma
In-silico Pharma
Accelerating Innovation with Precision and Expertise
Proone Labs equips in-silico pharma companies with essential tools and expertise to successfully launch their products while overcoming challenges such as inaccurate models, limited data access, regulatory hurdles, target identification, competition, and validation needs.
Proone Labs equips in-silico pharma companies with essential tools and expertise to successfully launch their products while overcoming challenges such as inaccurate models, limited data access, regulatory hurdles, target identification, competition, and validation needs.
Proof of concept
Target identification
Platform validation
High-Quality Experimental Data Generation
Regulatory Compliance
Sf
Silico Pharma
Biotech Startups
Catalyzing Biotech Ventures from Concept to Market
Proone Labs propels biotech start-ups to success, offering expert guidance in business strategy and planning, fundraising, IP protection, compliance, R&D, commercialization, and more, while also leveraging its wide network of industry players.
Proone Labs propels biotech start-ups to success, offering expert guidance in business strategy and planning, fundraising, IP protection, compliance, R&D, commercialization, and more, while also leveraging its wide network of industry players.
Product Evaluation
Commercialization Strategy
Market Analysis/Go to Market Strategy Development
Network Expansion
Regulations
Es
Entrepreneurs
Biotech Investors
Solidifying Investment Success with Expert Biotech Insights
Proone Labs offers a comprehensive suite of services for investment institutions and VC firms in the biotech sector, including market analysis, due diligence, strategic consulting, network connections, and IP evaluation, to enhance their operations and portfolio company success.
Proone Labs offers a comprehensive suite of services for investment institutions and VC firms in the biotech sector, including market analysis, due diligence, strategic consulting, network connections, and IP evaluation, to enhance their operations and portfolio company success.
Project & IP Evaluation
Risk assessment
Identification of Potential Partnerships & Acquisitions
Regulatory Advisory
Pivotal Strategy Development
In
Investors
Our partners
Why choose us
Uncompromized results with Our Stringent Quality Control
At Proone Labs, we ensure that every piece of data generated and reported is of the highest precision, ready to meet and exceed any challenge.
Seamless method integration
Our scientific team is dedicated to assisting you with your workflow, from compound characterization to pharmacokinetics and pharmacodynamics studies, bolstering your biomedical and preclinical development efforts.
Collaborative partnership every step of the way
At Proone Labs, we treat each project uniquely, engaging in close collaboration with project partners to ensure productive efforts, streamlined workflows, and high-quality outcomes.
Expert-led team at your service
Proone Labs is built upon a foundation of skilled professionals, supporting every service we offer. From laboratory work to project planning and final development stages, our team is equipped with hands-on experience, ready to provide you with expert guidance.
Maximizing time and resource efficiency
Our expertise is now at your service. Preserve your most valuable resource — your time — by doing it right.
Good Laboratory Practice (GLP) compliance
Proone Labs follows all the regulatory norms and is a GLP-compliant institution. Thus, we can provide both GLP and non-GLP compliant services.
About us
Founded with the vision of empowering R&D organizations and individual innovators, Proone Labs brings together a team of experts specializing in cutting-edge technology development. Our founders possess a rich history in navigating the intricate journey of new product development, including achieving FDA approvals across various projects.
As we've evolved, Proone Labs has established itself as an all-encompassing preclinical partner, accelerating the journey from innovative concept to market readiness for entities across the pharmaceutical spectrum. We commit to the success of both traditional and digital pharma initiatives, ensuring that every project we touch benefits from our expertise. Our mission is to empower every player in the field, from startups to investors, with the tools and insights needed to realize the full potential of their technologies and ideas, making significant impacts in the pharmaceutical and biotech industries.
As we've evolved, Proone Labs has established itself as an all-encompassing preclinical partner, accelerating the journey from innovative concept to market readiness for entities across the pharmaceutical spectrum. We commit to the success of both traditional and digital pharma initiatives, ensuring that every project we touch benefits from our expertise. Our mission is to empower every player in the field, from startups to investors, with the tools and insights needed to realize the full potential of their technologies and ideas, making significant impacts in the pharmaceutical and biotech industries.
The Founders
Ligand Binding Assays: LBAs continue to be the primary tool used in the biopharmaceutical sciences to quantitate proteins and anti-drug antibodies in biological fluids and tissues.
Dr. Lucy Abgaryan
PhD, MBA
Co-Founder & CEO
Dr. Lucy Abgaryan
Close
Dr. Abgaryan has more than 15 years of experience in the field of drug discovery and small molecule pharmacology. Dr. Abgaryan had a track record of 3 IND submissions, a number of PubChem molecular structure discoveries and one FDA - approved drug, Ozanimod, for treatment of Multiple Sclerosis and Ulcerative Colitis. Throughout her career, she developed multiple assays for high throughput drug screening and a number of genetically modified cell lines as essential tools in drug discovery.
Dr. Abgaryan She is the invitro-pharmacologist for the lead discovery of drugs targeting KOR Antagonist and V1aR Antagonist receptors that are currently in clinical phases 2 and 1 in the pipeline. She directly contributed to 7 start-ups and incubators from early-stage set-up, business development and market entry. i. Dr. Lucy Abgaryan has an undergraduate degree in physics and PhD in Biophysics from Yerevan State University, and an MBA from the University of California San Diego (UCSD).
Dr. Abgaryan continues her education at The Scripps Research Institute as a postdoctoral fellow developing small molecule drugs for a number of disorders.
Dr. Gor Sarkisyan
PhD
Co-Founder & CEO
Dr. Lucy Abgaryan
Close
Dr. Abgaryan has more than 15 years of experience in the field of drug discovery and small molecule pharmacology. Dr. Abgaryan had a track record of 3 IND submissions, a number of PubChem molecular structure discoveries and one FDA - approved drug, Ozanimod, for treatment of Multiple Sclerosis and Ulcerative Colitis. Throughout her career, she developed multiple assays for high throughput drug screening and a number of genetically modified cell lines as essential tools in drug discovery.
Dr. Abgaryan She is the invitro-pharmacologist for the lead discovery of drugs targeting KOR Antagonist and V1aR Antagonist receptors that are currently in clinical phases 2 and 1 in the pipeline. She directly contributed to 7 start-ups and incubators from early-stage set-up, business development and market entry. i. Dr. Lucy Abgaryan has an undergraduate degree in physics and PhD in Biophysics from Yerevan State University, and an MBA from the University of California San Diego (UCSD).
Dr. Abgaryan continues her education at The Scripps Research Institute as a postdoctoral fellow developing small molecule drugs for a number of disorders.
We have been working with Proone Labs for about a year on our preclinical PK studies. The Proone Labs scientists are knowledgeable and readily available for discussions. We hired Proone Labs to develop a method to characterize blood levels of our compound. Through Proone Labs' diligence, we discovered that the standard LCMS method would not work for our compound and Proone Labs helped in that and developed the method that we used throughout our development.
Proone Labs is an exceptional service provider when it comes to amino acid analysis. We were searching for a solution to perform trace-amount characterization on amino acids, but we didn't have the methods available. Thankfully, we were referred to Proone Labs, who worked closely with us to develop and validate an LCMS acquisition method for sample preparation, acquisition, and analysis of the amino acids we were interested in. Their expertise and dedication were invaluable to the success of our project.
Proone Labs played a vital role in the success of our research project on virus-based therapies for bacterial infections. Their expertise in the characterization and quantitation of viral and host proteins was invaluable to us. Thanks to their partnership, we were able to develop a methodology that allowed us to assess the purity of the viral proteins we were interested in, and this methodology is now fully integrated into our workflow. We couldn't have done it without them.
100
%